44 completed, 13 terminated, 7 unknown, 2 withdrawn. 68 Phase 2, 11 Phase 1, 7 Phase 3.
Follow Interferon alpha-2: new trials by email Literature Review of Interferon alpha-2 trials Research Report on Interferon alpha-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1 Ligand Inhibitor - HLA-A2 Positive Cells Present, Refractory Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 1 | 2024-11-13 | 2026-02-25 |
| Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer Biopsy, Biospecimen Collection, Celecoxib - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 5 | 2024-02-16 | 2026-08-31 |
| Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients Recombinant Interferon Alfa-2b, Rintatolimod - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2020-11-17 | 2026-01-13 |
| Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery EC Aspirin, Radical Prostatectomy, Recombinant Interferon Alfa-2b - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 | Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 12 | 2019-11-29 | 2026-06-09 |
| Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer Tumor Infiltrating Lymphocytes (TIL), Interferon Alfa 2A, Carboplatin - Ovarian Cancer Recurrent | Phase 1 / Phase 2 | Unknown | Leiden University Medical Center | 12 | 2018-08-01 | 2021-04-01 |
| Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver Celecoxib, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Metastatic Carcinoma in the Liver, Recurrent Colorectal Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 19 | 2018-04-19 | 2022-03-02 |
| Interferon-α After DLI for the Prevention of Relapse Interferon Alfa-2b - Leukemia | Phase 1 / Phase 2 | Unknown | Peking University People's Hospital | 42 | 2015-12-01 | 2016-09-29 |
| Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection TG-2349, Ribavirin, Interferon Alfa-2a - Hepatitis C, Chronic | Phase 2 | Completed | TaiGen Biotechnology Co., Ltd. | 25 | 2015-05-01 | 2023-07-14 |
| αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies DC vaccine, Celecoxib, Interferon Alfa-2b - Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface, Malignant Peritoneal Mesothelioma | Phase 1 / Phase 2 | Completed | David Bartlett | 64 | 2014-07-01 | 2020-07-20 |
| Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients Human Serum ALbumin/interferon alpha2a, Pegasys - Chronic Hepatitis B | Phase 1 / Phase 2 | Completed | Beijing Bio-Fortune Ltd. | 32 | 2013-11-01 | 2014-11-17 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2013-03-25 | 2026-07-21 |
| Sequential Therapy in Metastatic Renal Cell Carinoma Avastin in combination with Roferon-A, Afinitor, TKI: Sutent, Nexavar or Votrient - Metastatic Renal Cell Carcinoma | Phase 2 | Completed | Central European Society for Anticancer Drug Research | 22 | 2012-10-01 | 2019-02-06 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer Chemokin Modulatory Regimen (5 MU/m2), Chemokin Modulatory Regimen (10 MU/m2), Chemokin Modulatory Regimen (20 MU/m2) - Colorectal Cancer, Colorectal Carcinoma | Phase 1 / Phase 2 | Terminated | Roswell Park Cancer Institute | 15 | 2012-10-01 | 2023-10-27 |
| Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer Interferon Alfa-2b, p53 SLP - Recurrent Ovarian Cancer | Phase 1 / Phase 2 | Completed | Leiden University Medical Center | 15 | 2011-08-01 | 2014-01-07 |
| Pazopanib in Combination With Interferon Alfa 2-A, in Patients With Advanced Renal Cell Carcinoma Pazopanib + interferon alpha 2A - Advanced Renal Cell Carcinoma | Phase 1 / Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 53 | 2011-07-11 | 2022-03-10 |
| Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia Influenza Vaccine Trivalent Inactivated (TIV), Pegylated interferon (PEGrIFN-α, Pegasys), Interferon (IFNα, Roferon-A) - Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2011-04-01 | 2012-08-03 | |
| Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma lovastatin, interferon alfa-2b - Melanoma, Malignant Melanoma | Phase 2 | Withdrawn | NeoPlas Innovation | 250 | 2009-12-01 | 2009-09-09 |
| Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | Case Comprehensive Cancer Center | 38 | 2009-11-11 | 2019-02-26 |
| Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer Interleukin-2, Interferon Alfa-2b, Bevacizumab - Metastatic Renal Cell Carcinoma | Phase 2 | Unknown | University of Aarhus | 118 | 2009-10-01 | 2014-12-02 |
Showing 20 of 68. Sign in to see all of them.
Carcinoma, Renal Cell (14) · Melanoma (10) · HIV Infections (6) · Hepatitis C (4) · Hepatitis C, Chronic (4) · Leukemia (4) · Acquired Immunodeficiency Syndrome (3) · Hematologic Neoplasms (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Brain Neoplasms (2) · Colorectal Neoplasms (2) · Hepatitis B, Chronic (2) · Kidney Neoplasms (2)
M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (8) · Roswell Park Cancer Institute (6) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Hoffmann-La Roche (3) · Merck Sharp & Dohme LLC (3) · Case Comprehensive Cancer Center (2) · Leiden University Medical Center (2) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Bio-Fortune Ltd. (1) · Central European Society for Anticancer Drug Research (1) · Centre Leon Berard (1) · Children's Oncology Group (1) · Dartmouth-Hitchcock Medical Center (1) · David Bartlett (1)
United States (41) · Germany (5) · Netherlands (5) · Switzerland (5) · France (4) · Spain (4) · United Kingdom (4) · Canada (3) · Italy (3) · Puerto Rico (3) · Russia (3) · China (2) · Czechia (2) · Finland (2) · Hungary (2)
Igor Puzanov (2) · Ahmad Tarhini (1) · Amar Safdar, MD (1) · Amer H Zureikat, MD (1) · Ana M. Aparicio, MD (1) · Anas Younes, MD (1) · Andrew Muir, M.D. (1) · Brian Rini (1) · Daniel George (1) · David L Bartlett, MD (1) · Ellis Levine, MD (1)
PMID 37146227, PMID 15079763, PMID 15282352, PMID 15563253, PMID 15685543, PMID 15867490, PMID 16115185, PMID 16439867, PMID 19622576, PMID 20622678, PMID 21664867, PMID 23803225, PMID 25851632, PMID 25900027, PMID 27101285, PMID 28291640, PMID 28620382, PMID 29152412, PMID 29392960, PMID 29563634, PMID 29774030, PMID 31371315, PMID 34327591, PMID 36848607
P30CA016672 (4), P01CA234212 (3), 2004 (1), 2008 (1), N01CM17101 (1), N01CM62202 (1), P01CA132714 (1), P30CA016056 (1), P30CA023108 (1), P30CA072720 (1), R01AI049141 (1), R01CA095648 (1), U01CA070172 (1), U01CA099118 (1), U10CA021115 (1)